{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fher3-trials-in-nsclc-epAFcP2Q","width":444,"version":"1.0","type":"rich","title":"Unpacking the Potential of HER3-Targeted Therapy in NSCLC","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/e65535c8-a5c4-41d6-a77a-c43faf6cd856/lung-her3-prp7140-pod773-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/666de2a0-617d-41a6-8485-f1944286b09b\" height=\"200\" width=\"100%\" title=\"Unpacking the Potential of HER3-Targeted Therapy in NSCLC\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast, Helena Yu, MD, and Rebecca S. Heist, MD, MPH, discuss ongoing clinical trials of HER3-targeted therapy for patients with advanced NSCLC and how these agents have the potential to change treatment options in this setting. "}